Skip to main content

Table 1 Antimicrobial activity of antimicrobial agents against Enterobacteriaceae collected globally between 2004 - 2013

From: Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013

 

MIC 90 (mg/L)

MIC range mg/L

% susceptible

% resistant

Enterobacteriaceae (n = 118,899)

    

AMK

8

≤0.5 – ≥ 128

96.9

1.8

AMC

≥64

≤0.12 – ≥ 64

43.5

46.2

AMP (n = 118,648)

≥64

≤0.5 – ≥ 64

13.0

80.4

FEP

16

≤0.5 – ≥ 64

88.7

8.8

CRO

64

≤0.06 – ≥ 128

72.3

25.7

IPM (n = 25,381)

1

≤0.06 – ≥ 32

97.1

0.9

LVX

≥16

≤0.008 – ≥ 16

79.0

18.4

MEM (n = 93,518)

0.25

≤0.06 – ≥ 32

97.0

2.3

MIN

16

≤0.5 – ≥ 32

74.9

13.1

TZP

64

≤0.06 – ≥ 256

84.0

9.4

TGC

1

≤0.008 – ≥ 32

97.0

0.6

Enterobacteriaceae, MDR (n = 9,372)

    

AMK

≥128

≤0.5 – ≥ 128

75.4

17.8

AMC

≥64

0.25 – ≥ 64

11.8

67.8

AMP (n = 9,371)

≥64

≤0.5 – ≥ 64

0.2

99.5

FEP

≥64

≤0.5 – ≥ 64

47.3

44.2

CRO

≥128

≤0.06 – ≥ 128

20.3

78.2

IPM (n = 1,158)

4

≤0.06 – ≥ 32

85.2

12.1

LVX

≥16

≤0.008 – ≥ 16

6.1

92.1

MEM (n = 8,214)

≥32

≤0.06 – ≥ 32

75.3

21.8

MIN

≥32

≤0.5 – ≥ 32

12.0

81.5

TZP

≥256

≤0.06 – ≥ 256

39.5

44.0

TGC

4

≤0.008 – ≥ 32

83.2

6.9

  1. AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; BL, β-lactamase; Car-R, carbapenem-resistant; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MDR, multidrug-resistant; MEM, meropenem; MIN, minocycline; PEN, penicillin; TZP, piperacillin-tazobactam; TGC, tigecycline; VAN, vancomycin.